https://www.edisongroup.com/publication/orr-impressive-in-phase-i-uv1-plus-keytruda/29531
Valuation: NOK3.65bn or NOK114 per share

This was the first time Ultimovacs’ vaccine was combined with PD-1/PD-L1 CPI and various CPI combinations with UV1 are being evaluated in all four Ultimovacs’ Phase II trials. The results provide comfort that the company has chosen the right combinations. One of the four Phase II trials is INITIUM, evaluating UV1 in combination with nivolumab and ipilimumab in melanoma as well. We increase the probability of success in our model to 25% from 20% in all indications, as we believe there is read across as long as tumours express telomerase and are known to respond to CPI treatment. Our updated valuation is NOK3.65bn or NOK114 per share (vs NOK3.18bn or NOK99.4 per share).

💥💥💥💥💥💥💥💥

Jeg fortår ennå ikke hvorfor selskaper bruker pengr på Edison. De skriver analye etter bestilling og betaling. Både TRVX og PHO har brukt Edison (kanskje bruker ennå).

https://nordiclifescience.org/promising-findings-about-ultimovacs-cancer-vaccine/?utm_source=rss&utm_medium=rss&utm_campaign=promising-findings-about-ultimovacs-cancer-vaccine

Tja... Nå har vi uansett fått anledning til å laste litt til kurs under det primærinnsider lastet på selv sist uke... Lykke til, alle sammen :)